Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05976243 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
A Phase 3 study of Chronic Inducible Urticaria, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 362
- Enrollment target
- 20
- Study locations
NCT05976243 is a Phase 3 study of Chronic Inducible Urticaria that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 362 participants, above the 144-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target (151% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05976243, a Phase 3 study of Chronic Inducible Urticaria, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 362 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs). The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Remibrutinib
Study Locations (20)
California
- Kern Research - Bakersfield
- Allergy and Asthma Specialists Group - Huntington Beach
- Antelope Valley Clinical Trials - Lancaster
Florida
- Florida Ctr Allergy Asthma Research - Aventura
- Sarasota Clinical Research - Sarasota
- Univ of South Florida Asthma Allergy and Immunology CRU - Tampa
Illinois
- Endeavor Health - Glenview
- Asthma and Allergy Center of Chicago S C - River Forest
Alabama
- Allervie Clinical Research - Birmingham
Arkansas
- Acuro Research Inc - Little Rock
Colorado
- Asthma and Allergy Associates P C - Colorado Springs
Georgia
- Aeroallergy Research Laboratories - Savannah
Idaho
- Treasure Valley Medical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2029-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05976243
The ClinicalTrials.gov registry entry for NCT05976243 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 144-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target (151% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inducible Urticaria appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05976243 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05976243 about?
NCT05976243 is a clinical study titled "A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines". This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LO...
What is the current status of trial NCT05976243?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 362 participants. The study started on 2023-12-07. Estimated completion is 2029-06-15.
What conditions does trial NCT05976243 study?
This clinical trial studies the following conditions: Chronic Inducible Urticaria.
What interventions are being tested in trial NCT05976243?
The interventions under investigation include: Placebo (OTHER), Remibrutinib (DRUG).
Who is sponsoring clinical trial NCT05976243?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05976243 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inducible Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
RECRUITING · Phase 3
-
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
COMPLETED · Phase 2
-
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.